Validering av ny avancerad DNA-diagnostik för förenklad och kostnadseffektiv analys av genetiska sjukdomar
| Diarienummer | |
| Koordinator | VANADIS DIAGNOSTICS AB |
| Bidrag från Vinnova | 3 615 363 kronor |
| Projektets löptid | november 2014 - maj 2016 |
| Status | Avslutat |
Syfte och mål
The goal of the project was to support development of Vanadis smart NIPT technology, from early stage concept to clinical validation. We have successfully proven the technology on clinical samples, collected by our partner at Karolinska Hospital (behovsägaren), and the manual assay has been implemented on prototype instruments.
Resultat och förväntade effekter
As a result of the successful project, PerkinElmer acquired Vanadis in December 2015. PerkinElmer is a US corporation that is the market leader in traditional prenatal diagnosis. Vanadis will now have financial back up to take the technology to commercial stage, including filing for CE-IVD.
Upplägg och genomförande
The project was focused on the work packages described in the application. The company was staffed accordingly and individual project plans for the individual WPs was generated. The main goal with the company remained intact thoughout the project, keeping the team focused on the execution.